(A weight-related condition is a health problem linked to excess weight, such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes, fatty liver disease, or sleep apnea.) Semaglutide (Ozempic, Wegovy, Rybelsus) Ozempic and Rybelsus are approved for type 2 diabetes
At the end of the run-in period, patients who remained inadequately controlled and had an HbA1c between 7% and 10% were randomized to placebo, JARDIANCE 10 mg, JARDIANCE 25 mg, or a reference comparator
These medications have these effects: Reducing appetite and increasing feelings of fullness Slowing how quickly food leaves the stomach Improving the bodys response to insulin Together, these effects help people eat less and lose weight over time
Patch formulations, by contrast, have struggled to demonstrate equivalent weight loss in published trials, with some showing only 812% reduction compared to placebo
These landmark studies, required by regulatory authorities including the EMA and MHRA , have provided reassuring evidence about the cardiovascular safety profile of this drug class
In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation
